Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints.

[1]  S. Locarnini,et al.  Combination Chemotherapy for Hepatitis B Virus , 2000, Drugs.

[2]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[3]  S. Lewin,et al.  Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. , 2002, Antiviral research.

[4]  R. J. Colonno,et al.  Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[5]  R. D. de Man,et al.  Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. , 2002, Journal of hepatology.

[6]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[7]  K. Eguchi,et al.  Viral load is a significant prognostic factor for hepatitis B virus‐associated hepatocellular carcinoma , 2002, Cancer.

[8]  S. Zeuzem,et al.  Viral dynamics in chronic hepatitis B patients during lamivudine therapy. , 2002, Liver.

[9]  Y. Wen,et al.  High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. , 2002, Blood.

[10]  M. Winters,et al.  Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication , 2002, Antimicrobial Agents and Chemotherapy.

[11]  A. Lok,et al.  World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.

[12]  F. Zoulim.  A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection , 2002, Drug safety.

[13]  L. Corey,et al.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. , 2001, The Journal of infectious diseases.

[14]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[15]  M. Sherman,et al.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.

[16]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[17]  H. Conjeevaram,et al.  Occult hepatitis B virus infection: A hidden menace? , 2001, Hepatology.

[18]  W. Delaney,et al.  Resistance of Hepatitis B Virus to Antiviral Drugs: Current Aspects and Directions for Future Investigation , 2001, Antiviral chemistry & chemotherapy.

[19]  Alan S. Perelson,et al.  Kinetics of Acute Hepatitis B Virus Infection in Humans , 2000, The Journal of experimental medicine.

[20]  J. Colacino,et al.  Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. , 2001, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[21]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[22]  J. Dienstag,et al.  Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. , 1999, The Journal of infectious diseases.

[23]  R. Tedder,et al.  A placebo‐controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection , 1999, Journal of viral hepatitis.

[24]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[25]  R. Colgrove,et al.  A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. , 1999, Antiviral research.

[26]  S. Locarnini,et al.  Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. , 2008, Liver.

[27]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.